PMID: 2123913Sep 1, 1990Paper

Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration

Journal of Hepatology
J FeveryJ De Groote

Abstract

Four consecutive patients with alcoholic cirrhosis and hepatorenal syndrome were treated with misoprostol, a synthetic methylester prostaglandin E1 analogue at twice the dosage advocated for anti-ulcer therapy (i.e., 0.4 mg four times per day orally) and albumin infusions. The mean urinary output obtained over the 3 days preceding misoprostol administration was 250, 315, 550 and 195 ml per 24 h, respectively, in the four patients, despite adequate volume expansion by plasma albumin to reach normal or high central venous pressure. Diuresis increased to 1450, 2440, 925 and 1300 ml, respectively, on days 2-4 after onset of therapy. Serum creatinine levels were 71, 51, 33 and 35 mg/l before and dropped to 26, 21, 13 and 17 mg/l during treatment. All patients had hyponatraemia (117-128 mequiv/l) which normalized, although they were continued on a low sodium intake of less than 10 mequiv per 24 h. Urinary sodium excretion increased from 0.4-3 mmol per 24 h, to 15-40 in the first two cases and only slightly to 3-5 in the last two patients. Three patients died after 10, 30 and 40 days due to oesophageal bleeding, encephalopathy or pulmonary infection, whereas one patient underwent an orthotopic liver transplantation when her serum crea...Continue Reading

References

Jun 1, 1979·The Journal of Clinical Endocrinology and Metabolism·R D ZipserR Horton
Sep 1, 1988·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R W SchrierJ Rodés
Jan 1, 1985·Journal of Hepatology·J H HenriksenN J Christensen
Apr 1, 1988·Journal of Hepatology·V ArroyoJ Rodés
Sep 8, 1988·The New England Journal of Medicine·K F Badr, I Ichikawa
Jul 1, 1987·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S GovindarajanR D Zipser
Nov 1, 1987·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M Epstein, M Lifschitz
Sep 1, 1986·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·H WernzeM Goerig
Mar 1, 1986·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·F J DudleyT B Reynolds
Nov 29, 1973·The New England Journal of Medicine·S IwatsukiT E Starzl
Aug 1, 1970·The American Journal of Medicine·M EpsteinJ P Merrill
Mar 1, 1984·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R M Pérez-AyusoJ Rodés
May 1, 1984·Kidney International·G F DiBona
Dec 16, 1982·The New England Journal of Medicine·D G BichetR W Schrier

❮ Previous
Next ❯

Citations

Mar 21, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A FabbriG Marchesini
Sep 1, 1992·Baillière's Clinical Gastroenterology·P Gentilini, G Laffi
Apr 6, 2004·Current Opinion in Pharmacology·Kassem Barada
Apr 1, 1996·Journal of Hepatology·Z AckermanD Rachmilewitz
May 3, 2000·Alimentary Pharmacology & Therapeutics·L DagherA Burroughs
Jul 18, 2002·Journal of Gastroenterology and Hepatology·Richard Moreau
Oct 16, 2001·Gut·L Dagher, K Moore
Feb 24, 2001·Pharmacotherapy·N M DaviesF Jamali
Jul 14, 2012·World Journal of Gastroenterology : WJG·Marek Hartleb, Krzysztof Gutkowski
Jan 7, 2014·Néphrologie & thérapeutique·Evangéline Pillebout
Aug 1, 1992·Lancet·M Fortier-BeaulieuJ Bourreile
Apr 9, 2005·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·Ana Rosa Rincón-SánchezJuan Armendáriz-Borunda
May 17, 2007·São Paulo Medical Journal = Revista Paulista De Medicina·Tércio Genzini, Fábio César Miranda Torricelli
Aug 30, 2001·Critical Care Clinics·M Kapoor, G Z Chan
Sep 1, 1990·Journal of Hepatology·V Arroyo, P Ginés
May 2, 2002·Journal of Gastroenterology and Hepatology·Anuchit Chutaputti
Jun 3, 2006·Nature Clinical Practice. Gastroenterology & Hepatology·Andrés Cárdenas, Pere Ginès
May 21, 2009·The American Journal of Gastroenterology·Guadalupe Garcia-TsaoUNKNOWN Members of Veterans Affairs Hepatitis C Resource Center Program
Sep 1, 2004·Alimentary Pharmacology & Therapeutics·S Møller, J H Henriksen
Apr 9, 2005·Alimentary Pharmacology & Therapeutics·P-T T PhamA H Wilkinson
May 1, 2010·AACN Advanced Critical Care·Elaine M Fisher, Diane K Brown
Aug 19, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Hani M WadeiThomas A Gonwa
Dec 6, 2006·Expert Review of Neurotherapeutics·Neal M DaviesKarina R Vega-Villa
Jul 23, 2005·Scandinavian Journal of Gastroenterology·Søren MøllerJens H Henriksen
Dec 11, 2002·Journal of Gastroenterology and Hepatology·Arun J Sanyal
Apr 6, 2004·The International Journal of Artificial Organs·A Santoro, E Mancini
Nov 30, 2000·Current Treatment Options in Gastroenterology·R PlanasJ Rodés
Feb 1, 1996·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·G Van Roey, K Moore
Nov 15, 2019·Nature Reviews. Nephrology·Juan Carlos Q VelezLuis A Juncos
Mar 10, 2001·Clinics in Liver Disease·R BatallerJ Rodés
Mar 1, 1993·Kidney International·M Levy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.